biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Sep 05, 2018 11:10am

129 Views

Post# 28565372

RE:RE:Ossianix - Novo Nordisk

Mark Day recently mentioned Ossianix as a company still working on transferrin receptor (TfR) single domain antibodies. Interestingly, the recent BiOasis MD&A stated that two promising single domain antibody candidates came out of the BiOasis/CQDM/Brains Canada collaboration. These have been selected for their BBB transport capability and efficacy in pharmacodynamic models. These will be added to the xB3 peptide vector family along with related IP, allowing the Company to pursue global commercialization of them, if warranted. Surely, the BBB crossing efficiency of xB3 was a good meter stick for determing the promise of the single domain antibodies that came out of the biOasis/CQDM/Brains Canada collaboration.Therefore, it is likely that these biOasis/CQDM/Brains Canada single domain antibodies are far superior to these Ossianix antibodies.

The recent biOasis/MedImmune publication really highighted the superiority of the melanotransferrin (MTfR) receptor approach (via xB3 peptide aka Mtfp, as well as full length MTf) relative to the antibody-mediated TfR approach. I discussed this a bit in a recent post from July.

BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market